genentech immunotherapy：SITC
SITC
This$50,000,one-yearfellowshipwillhelpsupportthedevelopmentofafemaleimmunotherapyexpertwhohasavestedinterestinfurtheringtheresearchand ...。其他文章還包含有：「Topics」、「Oncology&CancerImmunotherapy」、「TheFutureofImmunotherapyStartsHere」、「FDAApprovesGenentech'sImmunotherapyForPeople...」、「QuestfortheCure」、「Three-yearPhase1Follow」、「2023SITC」、「Advancesinthecancer」、「NewsF...
查看更多 離開網站
Topics
https://www.gene.com
A new framework for cancer immunotherapy research around the world.
Oncology & Cancer Immunotherapy
https://www.gene.com
We have the broadest and most diverse pipeline in oncology with more than 20 immunotherapy molecules. Since 2011, we have introduced 18 oncology medicines. All ...
The Future of Immunotherapy Starts Here
https://www.gene.com
Few scientific advances have transformed cancer care as quickly or broadly as immunotherapy. Yet, the need to develop new, more personalized ...
FDA Approves Genentech's Immunotherapy For People ...
https://www.gene.com
Today's landmark approval gives physicians and patients a new way to treat early lung cancer that has the potential to significantly reduce risk ...
Quest for the Cure
https://www.gene.com
Some antibody-based medicines are forms of immunotherapy that are precisely-designed to bind to specific areas of specific cancer cells — ...
Three-year Phase 1 Follow
https://investors.biontech.de
Autogene cevumeran is being jointly developed by BioNTech and Genentech and is currently being evaluated in three ongoing randomized Phase 2 ...
2023 SITC
https://www.sitcancer.org
This $100,000, one-year cancer immunotherapy fellowship helps support the development of a female immunotherapy expert who has an MD, a PhD or a combined MD/PhD ...
Advances in the cancer
https://www.roche.com
We're partnering with many different stakeholders to find the most effective way for the immune system to identify and kill cancer cells.
News Features
https://www.gene.com
On March 18, 2019, the FDA approved Genentech’s immunotherapy, in combination with chemotherapy (carboplatin and etoposide), for the initial (first-line) ...